| |||||||||||
- Description
- Phenotype
- Genes & alleles
- Genotyping
- Health & husbandry
- References
- Purchasing information
- Terms of Use
Description
Strain Information
Type Congenic; Major Histocompatibility Congenic; Mutant Strain; Additional information on Genetically Engineered and Mutant Mice. Visit our online Nomenclature tutorial. Additional information on Congenic nomenclature. Mating System Homozygote x Homozygote (Female x Male) 01-MAR-06 Species laboratory mouse Background Strain C57BL/10Sn Donor Strain DBA/2 Generation N16F105 (03-JAN-08)
View larger imageAppearance
black
Related Genotype: a/a
Control Information
| Control | ||
|---|---|---|
| 000666 C57BL/10SnJ | ||
| Considerations for Choosing Controls | ||
Related Strains
Strains carrying H2d allele
005308 B10.Cg-H2d Tg(TcraCl4,TcrbCl4)1Shrm/ShrmJ 005534 B10.Cg-H2d Tg(Ins2-HA)165Bri/ShrmJ 005895 B10.Cg-Thy1a H2d Tg(TcraCl1,TcrbCl1)1Shrm/J 000462 B10.D2-H2d/n2SnJ 000460 B10.D2-Hc0 H2d H2-T18c/o2SnJ 000461 B10.D2-Hc0 H2d H2-T18c/oSnJ 003147 B10.D2-Hc1 H2d H2-T18c/nSnJ-Tg(DO11.10)10Dlo/J 000360 B6.C-H2d Mdmg1BALB/cBy/aByJ 000359 B6.C-H2d/bByJ 001893 BRVR.D2-H2d/J 000437 D1.C-H2d H2-T18c/SnJ 003153 WLC.C-H2d.GR-Mtv2/MorJ 003154 WLC.C-H2d/MorJ View Strains carrying H2d (13 strains)
000470 AK.M-H2m H2-T18a/nSnJ 005308 B10.Cg-H2d Tg(TcraCl4,TcrbCl4)1Shrm/ShrmJ 003147 B10.D2-Hc1 H2d H2-T18c/nSnJ-Tg(DO11.10)10Dlo/J 004306 NOD.CBALs-Hc1/LtJ
000645 A/HeJ 000646 A/J 000647 A/WySnJ 000648 AKR/J 000460 B10.D2-Hc0 H2d H2-T18c/o2SnJ 000461 B10.D2-Hc0 H2d H2-T18c/oSnJ 000657 CE/J 000671 DBA/2J 007048 DBA/2J-Gpnmb+/SjJ 001800 FVB/NJ 001491 FVB/NMob 000674 I/LnJ 001303 NOD.CB17-Prkdcscid/J 001976 NOD/ShiLtJ 000684 NZB/BlNJ 000682 RF/J 000688 ST/bJ 000689 SWR/J
Additional Web Information
Genetic Quality Control Annual Report
JAX® NOTES, October 1989; 439. Splenic Melanosis in Black Mice.
Phenotype
Phenotype Information
Mouse Phenome Database
This mouse can be used to support research in many areas including:
H2d relatedImmunology and Inflammation Research
CD Antigens, Antigen Receptors, and Histocompatibility Markers
Hc1 relatedImmunology and Inflammation Research
CD Antigens, Antigen Receptors, and Histocompatibility Markers
Immunodeficiency
specific complement deficiency, control
Research Tools
Immunology and Inflammation Research
specific complement deficiency, C5 complement, control
Genes & Alleles
Gene & Allele Information
| Allele Symbol | H2d | ||
|---|---|---|---|
| Allele Name | d variant | ||
| Allele Type | Spontaneous | ||
| Gene Symbol and Name | H2, histocompatibility-2, MHC | ||
| Chromosome | 17 | ||
| Gene Common Name(s) | H-2; MHC-II; | ||
| General Note | The d variant has been observed in the following strains: DBA/2, DBA/2J BALB/c, BALB/cByJ, BALB/cJ, C57BLKS, NZB. | ||
| Allele Symbol | Hc1 | ||
| Allele Name | sufficient | ||
| Allele Type | Not Applicable | ||
| Common Name(s) | C5 sufficient; C5-s; C5-suf; | ||
| Gene Symbol and Name | Hc, hemolytic complement | ||
| Chromosome | 2 | ||
| Gene Common Name(s) | C5; C5a; CPAMD4; FLJ17816; FLJ17822; He; MGC142298; | ||
| General Note |
Hc was identified as a candidate gene for Abhr2 in a microarray analysis of lung mRNA from A/J, C3H/HeJ, and (A/J x C3H/HeJ)F1 x A/J backcross animals. Hc genotype shows statistically significant correlation to allergen-induced bronchial hyperresponsive phenotype. The C3H/HeJ allele does not have the 2 bp deletion and is associated with resistance to allergen-induced bronchial hyperresponsiveness. (J:108211) | ||
| Molecular Note | This allele does not contain the 2 base "TA" deletion found in the Hc0 allele and is found in the following mouse strains BALB/cJ, C57BL/6J, DBA/1J, and B10.D2/nSnJ. This is equivalent to the wild-type allele. [MGI Ref ID J:23983] | ||
| Gene Symbol and Name | H2-T18, histocompatibility 2, T region locus 18 | ||
| Chromosome | 17 | ||
| Gene Common Name(s) | H-2T18; TL Ag; Tla; thymus leukemia antigen; | ||
Genotyping
Genotyping Information
The Jackson Laboratory has not developed a genotyping protocol for H2 haplotypes. The following reference may helpful: Saha BK. J Immunol Meth 1996 Jul 17;194(1):77-83. (PMID: 8690943). Alternatively, haplotype-specific antibodies can be used with FACS.
Helpful Links
Genotyping resources and troubleshooting
References
References
Additional References
H2d relatedHc1 relatedAddis-Lieser E; Kohl J; Chiaramonte MG. 2005. Opposing regulatory roles of complement factor 5 in the development of bleomycin-induced pulmonary fibrosis. J Immunol 175(3):1894-902. [PubMed: 16034133] [MGI Ref ID J:107269]
Bakir HY; Tomiyama-Miyaji C; Watanabe H; Nagura T; Kawamura T; Sekikawa H; Abo T. 2006. Reasons why DBA/2 mice are resistant to malarial infection: expansion of CD3int B220+ gammadelta T cells with double-negative CD4- CD8- phenotype in the liver. Immunology 117(1):127-35. [PubMed: 16423048] [MGI Ref ID J:106141]
Bhadra S; Lozano MM; Payne SM; Dudley JP. 2006. Endogenous MMTV Proviruses Induce Susceptibility to Both Viral and Bacterial Pathogens. PLoS Pathog 2(12):e128. [PubMed: 17140288] [MGI Ref ID J:120299]
Buhlmann JE; Gonzalez M; Ginther B; Panoskaltsis-Mortari A; Blazar BR; Greiner DL; Rossini AA; Flavell R; Noelle RJ. 1999. Cutting edge: sustained expansion of CD8+ T cells requires CD154 expression by Th cells in acute graft versus host disease. J Immunol 162(8):4373-6. [PubMed: 10201970] [MGI Ref ID J:119788]
Chiorazzi N; Fox DA; Katz DH. 1977. Hapten-specific IgE antibody responses in mice. VII. Conversion of IgE non-responder strains to IgE responders by elimination of suppressor T cell activity. J Immunol 118(1):48-54. [PubMed: 299762] [MGI Ref ID J:5739]
Clarke SR; Barnden M; Kurts C; Carbone FR; Miller JF; Heath WR. 2000. Characterization of the ovalbumin-specific TCR transgenic line OT-I: MHC elements for positive and negative selection. Immunol Cell Biol 78(2):110-7. [PubMed: 10762410] [MGI Ref ID J:133645]
Croxford AL; Akilli-Ozturk O; Rieux-Laucat F; Forster I; Waisman A; Buch T. 2008. MHC-restricted T cell receptor signaling is required for alphabeta TCR replacement of the pre T cell receptor. Eur J Immunol 38(2):391-9. [PubMed: 18203137] [MGI Ref ID J:131357]
Dalloul AH; Ngo K; Fung-Leung WP. 1996. CD4-negative cytotoxic T cells with a T cell receptor alpha/beta intermediate expression in CD8-deficient mice. Eur J Immunol 26(1):213-8. [PubMed: 8566069] [MGI Ref ID J:112982]
El-Sawy T; Belperio JA; Strieter RM; Remick DG; Fairchild RL. 2005. Inhibition of polymorphonuclear leukocyte-mediated graft damage synergizes with short-term costimulatory blockade to prevent cardiac allograft rejection. Circulation 112(3):320-31. [PubMed: 15998678] [MGI Ref ID J:117219]
Fischer Lindahl K. 1997. On naming H2 haplotypes: functional significance of MHC class Ib alleles. Immunogenetics 46(1):53-62. [PubMed: 9148789] [MGI Ref ID J:41130]
Ford MS; Zhang ZX; Chen W; Zhang L. 2006. Double-negative T regulatory cells can develop outside the thymus and do not mature from CD8+ T cell precursors. J Immunol 177(5):2803-9. [PubMed: 16920915] [MGI Ref ID J:139556]
Fu G; Vallee S; Rybakin V; McGuire MV; Ampudia J; Brockmeyer C; Salek M; Fallen PR; Hoerter JA; Munshi A; Huang YH; Hu J; Fox HS; Sauer K; Acuto O; Gascoigne NR. 2009. Themis controls thymocyte selection through regulation of T cell antigen receptor-mediated signaling. Nat Immunol 10(8):848-56. [PubMed: 19597499] [MGI Ref ID J:151074]
Gershwin ME; Castles JJ; Ikeda RM; Erickson K; Montero J. 1979. Studies of congenitally immunologic mutant New Zealand mice. I. Autoimmune features of hereditarily asplenic (Dh/+) NZB mice; reduction of naturally occurring thymocytotoxic antibody and normal suppressor function. J Immunol 122(2):710-7. [PubMed: 310848] [MGI Ref ID J:12036]
Ghendler Y; Hussey RE; Witte T; Mizoguchi E; Clayton LK; Bhan AK; Koyasu S; Chang HC; Reinherz EL. 1997. Double-positive T cell receptor(high) thymocytes are resistant to peptide/major histocompatibility complex ligand-induced negative selection. Eur J Immunol 27(9):2279-89. [PubMed: 9341770] [MGI Ref ID J:133112]
Gubbels MR; Jorgensen TN; Metzger TE; Menze K; Steele H; Flannery SA; Rozzo SJ; Kotzin BL. 2005. Effects of MHC and gender on lupus-like autoimmunity in Nba2 congenic mice. J Immunol 175(9):6190-6. [PubMed: 16237116] [MGI Ref ID J:119371]
Klein J; Figueroa F; David CS. 1983. H-2 haplotypes, genes and antigens: second listing. II. The H-2 complex. Immunogenetics 17(6):553-96. [PubMed: 6407984] [MGI Ref ID J:7097]
Krupnick AS; Gelman AE; Barchet W; Richardson S; Kreisel FH; Turka LA; Colonna M; Patterson GA; Kreisel D. 2005. Murine vascular endothelium activates and induces the generation of allogeneic CD4+25+Foxp3+ regulatory T cells. J Immunol 175(10):6265-70. [PubMed: 16272276] [MGI Ref ID J:119348]
Laky K; Lewis JM; Tigelaar RE; Puddington L. 2003. Distinct requirements for IL-7 in development of TCR gamma delta cells during fetal and adult life. J Immunol 170(8):4087-94. [PubMed: 12682238] [MGI Ref ID J:125438]
Legge KL; Braciale TJ. 2005. Lymph node dendritic cells control CD8+ T cell responses through regulated FasL expression. Immunity 23(6):649-59. [PubMed: 16356862] [MGI Ref ID J:113311]
Mendiratta SK; Kovalik JP; Hong S; Singh N; Martin WD; Van Kaer L. 1999. Peptide dependency of alloreactive CD4+ T cell responses. Int Immunol 11(3):351-60. [PubMed: 10221647] [MGI Ref ID J:110542]
Miyashita N; Migita S; Moriwaki K. 1987. Effects of H-2 complex and non-H-2 background on urethane-induced chromosomal aberrations in mice. Mutat Res 176(1):59-67. [PubMed: 3099189] [MGI Ref ID J:109945]
Murphy DB. 1986. Overview: the murine MHC. In: Handbook of Experimental Immunology. Vol. 3, Genetic and Molecular Immunology. Blackwell Scientific Publ., Oxford. [MGI Ref ID J:30731]
Murphy WJ; Raziuddin A; Mason L; Kumar V; Bennett M; Longo DL. 1995. NK cell subsets in the regulation of murine hematopoiesis. I. 5E6+ NK cells promote hematopoietic growth in H-2d strain mice. J Immunol 155(6):2911-7. [PubMed: 7673708] [MGI Ref ID J:28582]
Oberg L; Johansson S; Michaelsson J; Tomasello E; Vivier E; Karre K; Hoglund P. 2004. Loss or mismatch of MHC class I is sufficient to trigger NK cell-mediated rejection of resting lymphocytes in vivo - role of KARAP/DAP12-dependent and -independent pathways. Eur J Immunol 34(6):1646-53. [PubMed: 15162434] [MGI Ref ID J:115484]
Porcellini S; Traggiai E; Schenk U; Ferrera D; Matteoli M; Lanzavecchia A; Michalak M; Grassi F. 2006. Regulation of peripheral T cell activation by calreticulin. J Exp Med 203(2):461-71. [PubMed: 16492806] [MGI Ref ID J:119147]
Poulin LF; Habran C; Stordeur P; Goldman M; McKenzie A; Van Snick J; Renauld JC; Braun MY. 2005. Interleukin-9 stimulates the production of interleukin-5 in CD4+ T cells. Eur Cytokine Netw 16(3):233-9. [PubMed: 16266865] [MGI Ref ID J:115764]
Reed-Loisel LM; Sullivan BA; Laur O; Jensen PE. 2005. An MHC class Ib-restricted TCR that cross-reacts with an MHC class Ia molecule. J Immunol 174(12):7746-52. [PubMed: 15944277] [MGI Ref ID J:109978]
Rodrigues OR; Moura RA; Gomes-Pereira S; Santos-Gomes GM. 2006. H-2 complex influences cytokine gene expression in Leishmania infantum-infected macrophages. Cell Immunol 243(2):118-26. [PubMed: 17316586] [MGI Ref ID J:120728]
Santiago ML; Montano M; Benitez R; Messer RJ; Yonemoto W; Chesebro B; Hasenkrug KJ; Greene WC. 2008. Apobec3 encodes Rfv3, a gene influencing neutralizing antibody control of retrovirus infection. Science 321(5894):1343-6. [PubMed: 18772436] [MGI Ref ID J:138778]
Sho M; Yamada A; Najafian N; Salama AD; Harada H; Sandner SE; Sanchez-Fueyo A; Zheng XX; Strom TB; Sayegh MH. 2002. Physiological mechanisms of regulating alloimmunity: cytokines, CTLA-4, CD25+ cells, and the alloreactive T cell clone size. J Immunol 169(7):3744-51. [PubMed: 12244168] [MGI Ref ID J:120408]
Sutton VR; Waterhouse NJ; Browne KA; Sedelies K; Ciccone A; Anthony D; Koskinen A; Mullbacher A; Trapani JA. 2007. Residual active granzyme B in cathepsin C-null lymphocytes is sufficient for perforin-dependent target cell apoptosis. J Cell Biol 176(4):425-33. [PubMed: 17283185] [MGI Ref ID J:119725]
Ueno T; Habicht A; Clarkson MR; Albin MJ; Yamaura K; Boenisch O; Popoola J; Wang Y; Yagita H; Akiba H; Ansari MJ; Yang J; Turka LA; Rothstein DM; Padera RF; Najafian N; Sayegh MH. 2008. The emerging role of T cell Ig mucin 1 in alloimmune responses in an experimental mouse transplant model. J Clin Invest 118(2):742-51. [PubMed: 18172549] [MGI Ref ID J:131045]
Varadhachary AS; Monestier M; Salgame P. 2001. Reciprocal induction of IL-10 and IL-12 from macrophages by low-density lipoprotein and its oxidized forms. Cell Immunol 213(1):45-51. [PubMed: 11747355] [MGI Ref ID J:115363]
Venkatesan P; Finch RG; Wakelin D. 1993. MHC haplotype influences primary Giardia muris infections in H-2 congenic strains of mice. Int J Parasitol 23(5):661-4. [PubMed: 8225770] [MGI Ref ID J:21687]
Wang L; Han R; Lee I; Hancock AS; Xiong G; Gunn MD; Hancock WW. 2005. Permanent survival of fully MHC-mismatched islet allografts by targeting a single chemokine receptor pathway. J Immunol 175(10):6311-8. [PubMed: 16272282] [MGI Ref ID J:119345]
Zhang ZX; Yang L; Young KJ; DuTemple B; Zhang L. 2000. Identification of a previously unknown antigen-specific regulatory T cell and its mechanism of suppression. Nat Med 6(7):782-9. [PubMed: 10888927] [MGI Ref ID J:118729]
Zhou P; Szot GL; Guo Z; Kim O; He G; Wang J; Grusby MJ; Newell KA; Thistlethwaite JR; Bluestone JA; Alegre ML. 2000. Role of STAT4 and STAT6 signaling in allograft rejection and CTLA4-Ig-mediated tolerance. J Immunol 165(10):5580-7. [PubMed: 11067913] [MGI Ref ID J:119580]
Zosky GR; Larcombe AN; White OJ; Burchell JT; von Garnier C; Holt PG; Turner DJ; Wikstrom ME; Sly PD; Stumbles PA. 2009. Airway hyperresponsiveness is associated with activated CD4+ T cells in the airways. Am J Physiol Lung Cell Mol Physiol 297(2):L373-9. [PubMed: 19482896] [MGI Ref ID J:151339]
Actor JK; Breij E; Wetsel RA; Hoffmann H; Hunter RL Jr; Jagannath C. 2001. A role for complement C5 in organism containment and granulomatous response during murine tuberculosis. Scand J Immunol 53(5):464-74. [PubMed: 11309154] [MGI Ref ID J:103981]
Addis-Lieser E; Kohl J; Chiaramonte MG. 2005. Opposing regulatory roles of complement factor 5 in the development of bleomycin-induced pulmonary fibrosis. J Immunol 175(3):1894-902. [PubMed: 16034133] [MGI Ref ID J:107269]
Girardi G; Berman J; Redecha P; Spruce L; Thurman JM; Kraus D; Hollmann TJ; Casali P; Caroll MC; Wetsel RA; Lambris JD; Holers VM; Salmon JE. 2003. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 112(11):1644-54. [PubMed: 14660741] [MGI Ref ID J:86845]
Karp CL; Grupe A; Schadt E; Ewart SL; Keane-Moore M; Cuomo PJ; Kohl J; Wahl L; Kuperman D; Germer S; Aud D; Peltz G; Wills-Karp M. 2000. Identification of complement factor 5 as a susceptibility locus for experimental allergic asthma. Nat Immunol 1(3):221-6. [PubMed: 10973279] [MGI Ref ID J:108211]
Kawikova I; Paliwal V; Szczepanik M; Itakura A; Fukui M; Campos RA; Geba GP; Homer RJ; Iliopoulou BP; Pober JS; Tsuji RF; Askenase PW. 2004. Airway hyper-reactivity mediated by B-1 cell immunoglobulin M antibody generating complement C5a at 1 day post-immunization in a murine hapten model of non-atopic asthma. Immunology 113(2):234-45. [PubMed: 15379984] [MGI Ref ID J:92933]
Kirimanjeswara GS; Mann PB; Pilione M; Kennett MJ; Harvill ET. 2005. The complex mechanism of antibody-mediated clearance of Bordetella from the lungs requires TLR4. J Immunol 175(11):7504-11. [PubMed: 16301658] [MGI Ref ID J:122156]
Mahesh J; Daly J; Cheadle WG; Kotwal GJ. 1999. Elucidation of the early events contributing to zymosan-induced multiple organ dysfunction syndrome using MIP-1alpha, C3 knockout, and C5-deficient mice. Shock 12(5):340-9. [PubMed: 10565608] [MGI Ref ID J:59655]
Miller CG; Cook DN; Kotwal GJ. 1996. Two chemotactic factors, C5a and MIP-1alpha, dramatically alter the mortality from zymosan-induced multiple organ dysfunction syndrome (MODS): C5a contributes to MODS while MIP-1alpha has a protective role. Mol Immunol 33(14):1135-7. [PubMed: 9047380] [MGI Ref ID J:38592]
Mocco J; Mack WJ; Ducruet AF; Sosunov SA; Sughrue ME; Hassid BG; Nair MN; Laufer I; Komotar RJ; Claire M; Holland H; Pinsky DJ; Connolly ES Jr. 2006. Complement component C3 mediates inflammatory injury following focal cerebral ischemia. Circ Res 99(2):209-17. [PubMed: 16778128] [MGI Ref ID J:123658]
Mori L; de Libero G. 1998. Genetic control of susceptibility to collagen-induced arthritis in T cell receptor beta-chain transgenic mice. Arthritis Rheum 41(2):256-62. [PubMed: 9485083] [MGI Ref ID J:134111]
Moulton RA; Mashruwala MA; Smith AK; Lindsey DR; Wetsel RA; Haviland DL; Hunter RL; Jagannath C. 2007. Complement C5a anaphylatoxin is an innate determinant of dendritic cell-induced Th1 immunity to Mycobacterium bovis BCG infection in mice. J Leukoc Biol 82(4):956-67. [PubMed: 17675563] [MGI Ref ID J:125190]
Niculescu T; Weerth S; Niculescu F; Cudrici C; Rus V; Raine CS; Shin ML; Rus H. 2004. Effects of complement C5 on apoptosis in experimental autoimmune encephalomyelitis. J Immunol 172(9):5702-6. [PubMed: 15100315] [MGI Ref ID J:89686]
Nilsson UR; Muller-Eberhard HJ. 1967. Deficiency of the fifth component of complement in mice with an inherited complement defect. J Exp Med 125(1):1-16. [PubMed: 4959665] [MGI Ref ID J:5016]
Ooi YM; Colten HR. 1979. Genetic defect in secretion of complement C5 in mice. Nature 282(5735):207-8. [PubMed: 492335] [MGI Ref ID J:6214]
Patel SN; Berghout J; Lovegrove FE; Ayi K; Conroy A; Serghides L; Min-oo G; Gowda DC; Sarma JV; Rittirsch D; Ward PA; Liles WC; Gros P; Kain KC. 2008. C5 deficiency and C5a or C5aR blockade protects against cerebral malaria. J Exp Med 205(5):1133-43. [PubMed: 18426986] [MGI Ref ID J:136298]
Pritchard MT; McMullen MR; Stavitsky AB; Cohen JI; Lin F; Medof ME; Nagy LE. 2007. Differential contributions of C3, C5, and decay-accelerating factor to ethanol-induced fatty liver in mice. Gastroenterology 132(3):1117-26. [PubMed: 17383432] [MGI Ref ID J:128218]
Redecha P; Tilley R; Tencati M; Salmon JE; Kirchhofer D; Mackman N; Girardi G. 2007. Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blood 110(7):2423-31. [PubMed: 17536017] [MGI Ref ID J:147022]
Tanaka D; Kagari T; Doi H; Shimozato T. 2006. Essential role of neutrophils in anti-type II collagen antibody and lipopolysaccharide-induced arthritis. Immunology 119(2):195-202. [PubMed: 16836650] [MGI Ref ID J:118551]
Wetsel RA; Fleischer DT; Haviland DL. 1990. Deficiency of the murine fifth complement component (C5). A 2-base pair gene deletion in a 5'-exon. J Biol Chem 265(5):2435-40. [PubMed: 2303408] [MGI Ref ID J:23983]
Wheat WH; Wetsel R; Falus A; Tack BF; Strunk RC. 1987. The fifth component of complement (C5) in the mouse. Analysis of the molecular basis for deficiency. J Exp Med 165(5):1442-7. [PubMed: 3572304] [MGI Ref ID J:8690]
Younger JG; Shankar-Sinha S; Mickiewicz M; Brinkman AS; Valencia GA; Sarma JV; Younkin EM; Standiford TJ; Zetoune FS; Ward PA. 2003. Murine complement interactions with Pseudomonas aeruginosa and their consequences during pneumonia. Am J Respir Cell Mol Biol 29(4):432-8. [PubMed: 14500254] [MGI Ref ID J:94613]
Zhou W; Farrar CA; Abe K; Pratt JR; Marsh JE; Wang Y; Stahl GL; Sacks SH. 2000. Predominant role for C5b-9 in renal ischemia/reperfusion injury. J Clin Invest 105(10):1363-71. [PubMed: 10811844] [MGI Ref ID J:120567]
Health & husbandry
Health & Colony Maintenance Information
Animal Health Reports
Room Number MP21
Colony Maintenance
Mating System Homozygote x Homozygote (Female x Male) 01-MAR-06 Diet Information LabDiet® 5K52/5K67
Purchasing information
Pricing, Supply Level & Notes, Controls, General Terms & Conditions
Pricing
| Pricing for USA, Canada and Mexico shipping destinations |
|
Weeks of Age Price (US dollars $) Gender Genotypes Provided 3-5 weeks $48.60 Female Homozygous for Hc1, Homozygous for H2d, Homozygous for H2-T18c $41.40 Male Homozygous for Hc1, Homozygous for H2d, Homozygous for H2-T18c 6 weeks $50.65 Female Homozygous for Hc1, Homozygous for H2d, Homozygous for H2-T18c $43.45 Male Homozygous for Hc1, Homozygous for H2d, Homozygous for H2-T18c 7 weeks $52.70 Female Homozygous for Hc1, Homozygous for H2d, Homozygous for H2-T18c $45.50 Male Homozygous for Hc1, Homozygous for H2d, Homozygous for H2-T18c 8 weeks $54.75 Female Homozygous for Hc1, Homozygous for H2d, Homozygous for H2-T18c $47.55 Male Homozygous for Hc1, Homozygous for H2d, Homozygous for H2-T18c 9 weeks $56.80 Female Homozygous for Hc1, Homozygous for H2d, Homozygous for H2-T18c $49.60 Male Homozygous for Hc1, Homozygous for H2d, Homozygous for H2-T18c 10 weeks $58.85 Female Homozygous for Hc1, Homozygous for H2d, Homozygous for H2-T18c $51.65 Male Homozygous for Hc1, Homozygous for H2d, Homozygous for H2-T18c
Additional Supply Details
| Pricing for International shipping destinations |
|
Weeks of Age Price (US dollars $) Gender Genotypes Provided 3-5 weeks $63.20 Female Homozygous for Hc1, Homozygous for H2d, Homozygous for H2-T18c $53.90 Male Homozygous for Hc1, Homozygous for H2d, Homozygous for H2-T18c 6 weeks $65.90 Female Homozygous for Hc1, Homozygous for H2d, Homozygous for H2-T18c $56.60 Male Homozygous for Hc1, Homozygous for H2d, Homozygous for H2-T18c 7 weeks $68.60 Female Homozygous for Hc1, Homozygous for H2d, Homozygous for H2-T18c $59.30 Male Homozygous for Hc1, Homozygous for H2d, Homozygous for H2-T18c 8 weeks $71.30 Female Homozygous for Hc1, Homozygous for H2d, Homozygous for H2-T18c $62.00 Male Homozygous for Hc1, Homozygous for H2d, Homozygous for H2-T18c 9 weeks $74.00 Female Homozygous for Hc1, Homozygous for H2d, Homozygous for H2-T18c $64.70 Male Homozygous for Hc1, Homozygous for H2d, Homozygous for H2-T18c 10 weeks $76.70 Female Homozygous for Hc1, Homozygous for H2d, Homozygous for H2-T18c $67.40 Male Homozygous for Hc1, Homozygous for H2d, Homozygous for H2-T18c
Additional Supply Details
|
|
|
Supply Details
| Standard Supply | Level 3. Up to 50 mice. Larger quantities or custom orders arranged upon request. |
|---|---|
| Supply Notes |
|
Control Information
| Control | ||
|---|---|---|
| 000666 C57BL/10SnJ | ||
| Considerations for Choosing Controls | ||
| USA, Canada and Mexico - Control Pricing Information for Genetically Engineered Mutant Strains. | ||
| International - Control Pricing Information for Genetically Engineered Mutant Strains. | ||
Payment Terms and Conditions
Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.
See Terms of Use tab for General Terms and Conditions
The Jackson Laboratory's Genotype Promise
The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.Ordering and Purchasing Information
Purchasing Information
JAX® Mice Orders
Surgical Services
Contact Information
Orders & Technical Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form
Terms of Use
Terms of Use
General Terms and Conditions
Contact information
General inquiries
Contracts Administration
| phone: | 207-288-6470 |
| fax: | 207-288-6655 |
JAX® Mice, Products & Services Conditions of Use
"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.No Warranty
MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.
In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.
No Liability
In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. In purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.
MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.
The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.
Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.